

## Detailed results on aldoxorubicin presented

Detailed results of the Phase IIb trial of aldoxorubicin in first-line STS patients presented at the annual meeting of ASCO (top-line results were reported in several press releases) continue to show the drug's superior efficacy and safety profile over doxorubicin. The 400-patient, FDA SPA-sanctioned Phase III trial in second-line STS is progressing well with targeted completion of accrual in 2015 and possible top-line readout in 2016, a major value inflection point if the data are positive.

Year end	Revenue (\$m)	PBT* (\$m)	EPS* (\$)	DPS (\$)	P/E (x)	Yield (%)
12/12	0.1	(18.9)	(0.82)	0.0	N/A	N/A
12/13	0.3	(23.4)	(0.71)	0.0	N/A	N/A
12/14e	0.0	(35.7)	(0.71)	0.0	N/A	N/A
12/15e	0.0	(43.9)	(0.86)	0.0	N/A	N/A

Note: \*PBT and EPS are normalised, excluding intangible amortisation, exceptional items and share-based payments.

### Detailed Phase IIb aldoxorubicin results

Investigators of the Phase IIb trial of aldoxorubicin in first-line soft tissue sarcoma (STS) presented the baseline, safety and efficacy data of the trial at the annual meeting of ASCO held from 31 May to 2 June in Chicago. The additional data on response, in particular the percentage of patients with any tumour shrinkage, not only continue to demonstrate aldoxorubicin's superiority over doxorubicin, but also showed that doxorubicin had resulted in tumour shrinkage by central lab review. Previously the central lab review recorded 0% of response for doxorubicin because these tumour shrinkages failed to meet the partial response cut-off, and the result caused some concern among investors as doxorubicin has historically achieved some, albeit modest, response in STS. In our opinion, this new disclosure should have calmed the fear that doxorubicin underperformed, and therefore, aldoxorubicin's superior efficacy was questionable in the Phase IIb trial.

### Events to watch in 2014

Results that should affect the stock include preliminary data from the Phase II GBM trial and overall survival (OS) of the Phase IIb first-line STS. Positive OS data from the Phase IIb present a high bar because of the trial's relatively small size. We should note that the primary endpoint of the SPA-sanctioned Phase III second-line STS trial is PFS, not OS.

### Valuation: \$438m suggests upside potential

We have updated our risk-adjusted NPV of CytRx to \$438m or \$8.67/share (previously \$466m), with the principal change being our decreased forecast of the cash position at the end of 2014 and 2015, reflecting increased R&D cost estimates after Q114 actual results.

## Pharma & biotech

12 June 2014

**Price** US\$5.0  
**Market cap** US\$280m

Net cash (\$m) 31 March 2014	112.6
Shares in issue	56.06m
Free float	87%
Code	CYTR
Primary exchange	NASDAQ
Secondary exchange	N/A

### Share price performance



%	1m	3m	12m
Abs	57.9	1.2	127.1
Rel (local)	52.5	(2.8)	90.0
52-week high/low	US\$8.0	US\$2.0	

### Business description

CytRx is a US biopharmaceutical company focused on oncology. The company's novel technology platform (albumin-binding linkers) provides targeted delivery of chemotherapy to tumours. Lead programme aldoxorubicin is in Phase III for second-line STS and currently in Phase II for GBM and Kaposi's sarcoma.

### Next events

Start of Phase II in second-line SCLC	Q314
Preliminary data from Phase II GBM trial	H214
OS data from Phase IIb first-line STS	H214

### Analysts

Jason Zhang PhD	+1 646 653 7027
Dr Mick Cooper	+44 (0)20 3077 5734

[healthcare@edisongroup.com](mailto:healthcare@edisongroup.com)

[Edison profile page](#)

## Aldoxorubicin Phase IIb detailed data

Investigators of the Phase IIb trial of aldoxorubicin in first-line soft tissue sarcoma (STS) presented the baseline, safety and efficacy data of the trial at the annual meeting of ASCO held from 31 May to 2 June in Chicago. The additional data on response, in particular the percentage of patients with any tumour shrinkage, not only continue to demonstrate aldoxorubicin's superiority over doxorubicin, but also showed that doxorubicin had resulted in tumour shrinkage by central lab review. Previously the central lab review recorded 0% of response for doxorubicin because these tumour shrinkages failed to meet the "RECIST 1.1" partial response cut-off "of  $\geq 30\%$ ", and the result caused some concern among investors as doxorubicin has historically achieved some, albeit modest, response in STS. In our opinion, this new disclosure should have calmed the fear that doxorubicin underperformed, and therefore, aldoxorubicin's better efficacy was questionable in the Phase IIb trial. The complete Phase IIb data are listed in Exhibit 1.

<b>Exhibit 1: Phase IIb first-line STS trial results</b>				
	<b>Aldoxorubicin</b>		<b>Doxorubicin</b>	
Treatment	Aldoxorubicin, 350mg/m <sup>2</sup> , (260mg/m <sup>2</sup> dox equiv.), Every 3wk up to 6 cycles		Doxorubicin, 75mg/m <sup>2</sup> , Every 3wk up to 6 cycles	
N	83		40	
ECOG, (%)				
0-1	96%		92%	
2	4%		8%	
Histology:				
Leiomyosarcoma	34%		35%	
Liposarcoma	16%		15%	
Fibrosarcoma	14%		10%	
Synovial sarcoma	6%		10%	
Other	30%		30%	
Safety: (grade 3/4 treatment emerging adverse events)				
Neutropenia	40%		20%	
Neutropenic fever	16%		18%	
Thrombocytopenia	6%		5%	
Anaemia	13%		20%	
Nausea/vomiting	7%		0%	
Mucositis	11%		3%	
Fatigue/weakness	6%		5%	
# with >10% decrease in LVEF	24%		33%	
# with >15% decrease in LVEF	10%		24%	
# with $\leq 50\%$ of expected institutional normal	0%		6%	
Efficacy:	Investigator		Central lab	
	Aldoxorubicin	Doxorubicin	Aldoxorubicin	Doxorubicin
PFS, mths	8.4	4.7	5.7	2.8
p value	0.0004		0.014	
HR	0.419 (0.25-0.69)		0.584 (0.37-0.93)	
p value	0.0007		0.024	
PFS at 6 mths	68.1%	36.6%	45.7%	22.9%
p value	0.002		0.020	
Overall response:				
CR	2.4%		0.0%	
PR	19.3%		23.8%	
ORR	21.70%		23.8%	
<b>Any tumour shrinkage</b>	<b>64.5%</b>		<b>41.2%</b>	

Source: Company reports and ASCO 2014

## Financials

---

CytRx reported net income in Q114 of \$4.7m, compared with a net loss of \$6.9m in Q113, mainly because of a recognised non-cash gain of \$14.7m on the valuation of warrant derivative liabilities related to warrants issued in August 2011 and July 2009. R&D expenses for the quarter were \$7.0m, including \$4.9m for aldoxorubicin, compared to \$3.2m for Q113. The company ended the quarter, which included the net \$81m February equity raise, with cash, cash equivalents and short-term investment of \$112.6m.

We have updated our financial model, mainly to increase R&D cost estimates based on Q114 actual results and the company's guidance on trial progress. We now estimate R&D expenses in 2014 and 2015 will be \$33.5m and \$36.9m, respectively, compared to \$22.7m and \$25m, previously. We continue to estimate that the cash on hand should support the company's operation into 2016.

## CytRx datasheet

### Exhibit 2: CytRx's R&D pipeline summary

Product	Indication	Stage	Notes
Aldoxorubicin	Second-line soft tissue sarcoma (STS)	Phase III	400-pt Phase III, SPA-sanctioned study of aldoxorubicin vs physician's choice of five chemotherapy regimens in relapsed, or refractory STS. OS is primary endpoint. Aldoxorubicin allowed to be dosed to progression. Trial started in March 2014.
		Phase I	25-pt Phase Ib/IIa study included 13 advanced STS patients tested at the maximum tolerated dose (MTD) (350mg/m <sup>2</sup> ): showed partial response in 39%, stable disease in 54%, clinical benefit in 77%, median PFS of 11.3 months and OS of 21.7months, no acute cardiotoxicity and acceptable safety and tolerability at doses equal to 3.5x the standard doxorubicin dose.
	First-line STS	Phase IIb	123-pt trial of 350mg/m <sup>2</sup> of aldoxorubicin (n=83) or 75mg/m <sup>2</sup> doxorubicin (n=40) every three weeks for up to six cycles with metastatic, locally advanced or unresectable STS. Reported PFS of 8.4 mths vs 4.7 mths (investigator assessed, or IA, p=0.0002); Hazard ratio (HR) of 0.37 (95% CI 0.212 to 0.643, p=0.0004); 5.7 mths vs 2.8 mths (central lab review, or CLR, p=0.018), HR of 0.59 (95% CI 0.36 to 0.96, p=0.034). Six-month PFS 67.1% vs 36.1% (p=0.005, IA) and 46.8% vs 23.7% (p=0.038, CLR). Final ORR is 25.4% vs 5.4% (IA) and 23% vs 0% (CLR).
	Second-line glioblastoma multiforme (GBM)	Phase II ready	FDA approval for 28-pt Phase IIb trial in recurrent GBM following first-line chemotherapy (temozolomide). Currently enrolling patients, with preliminary results targeted for Q314. Positive preclinical data in animal model of GBM.
	AIDS-related Kaposi's sarcoma	Phase II	Up to 30-pt Phase II study started in Q114. Standard of care is liposomal doxorubicin (Doxil), but this is often sub-optimal due to toxicity and/or a lack of clinical response.
	Second-line SCLC	Phase IIb	Planned 132-pts Phase IIb trial comparing aldox or topotecan (randomised 1:1). Trial to start in Q314.
	First-line STS	Phase Ib/II	Up to 30 pts trial testing the combination of aldox and ifosfamide; planned to start in Q314.
	Metastatic solid tumour	Phase Ib/II	Up to 30 pts trial testing the combination of aldox and gemcitabine: planned to start in Q314

Source: Edison Investment Research

### Exhibit 3: Competing STS therapies in Phase III development

Product (company)	Setting	Population	Design/primary endpoint	Expected read-out	Notes
Aldoxorubicin (CytRx)	Second-line	Relapsed/refractory or intolerant to previous chemo	400-pt study of aldoxorubicin vs physician's choice. Primary endpoint: OS.	2016	Covered by SPA, Started in Q114.
TH-302 (Threshold)	First-line	Locally advanced, unresectable or metastatic	620-pt study of doxorubicin ± TH-302. Primary endpoint: OS.	H115	Covered by SPA. Interim OS analysis in H114, final OS data in H115.
Eribulin (Eisai)	Second-line	Locally advanced, unresectable or metastatic L-sarcoma	450-pt study of eribulin vs dacarbazine. Primary endpoint: OS.	H115	L-sarcoma includes liposarcoma or leiomyosarcoma; failed first-line anthracycline.
Trabectedin (Zeltia/J&J)	Second-line	Locally advanced, unresectable or metastatic L-sarcoma	570-pt study of trabectedin vs dacarbazine. Primary endpoint: OS.	H114	L-sarcoma subtypes only; failed first-line anthracycline.

Source: Threshold Pharmaceuticals, Zeltia, Edison Investment Research

### Exhibit 4: Selected Phase III efficacy results in STS

Product (company)	Setting	Treatment regimen	Study	No (n)	Median PFS (mths)	CR (%)	PR (%)	SD (%)	Clinical benefit (%)	Reference
Aldoxorubicin (CytRx)	First-line	Monotherapy	Phase IIb	123	8.4	2.4	19.3	N/A	N/A	ASCO 2014
	Second/third-line		Phase I/II	13	6.4	0	39	54	93	Chawla et al, ASCO 2012
Doxorubicin	First-line	Monotherapy	Phase IV	167	4.3	7	18	45	70	Nielsen et al, Sarcoma 2000
			Phase IV	455	4.6	0	13	46	59	EORTC 62012, ESMO 2012
Votrient (GSK)	Second-line	Monotherapy	Phase III	369	4.6	0	4	N/A	-	Prescribing information
TH-302 (Threshold)	First-line	Combo with doxorubicin	Phase I/II	91	6.7	2	34	48	84	Phase II, CTOS 2012

Source: CytRx, Sarcoma J, CTOS, ESMO, ASCO, GSK. Note: CR=complete response, PR=partial response, SD=stable disease.

**Exhibit 5: Financial summary**

	\$000s	2011	2012	2013	2014e	2015e
Year end 31 December		IFRS	IFRS	IFRS	IFRS	IFRS
<b>PROFIT &amp; LOSS</b>						
Revenue		250	100	300	0.0	0.0
Cost of Sales		0	0	0	0	0
Gross Profit		250	100	300	0	0
R&D Expenses		15,491	12,685	17,500	33,538	36,892
SG&A Expenses		7,317	8,353	10,274	8,981	9,071
EBITDA		(21,958)	(18,985)	(23,489)	(35,888)	(43,963)
Operating Profit (before amort and except)		(22,006)	(19,042)	(23,549)	(36,018)	(44,083)
Intangible Amortisation		(48)	(57)	(60)	(3,250)	(2,000)
Exceptionals		7,915	2,767	(20,210)	14,703	0
Other		(395)	(1,762)	(3,802)	(3,210)	(1,900)
Operating Profit		(14,534)	(18,094)	(47,622)	(27,776)	(47,983)
Net Interest		207	132	138	300	200
Profit Before Tax (norm)		(21,799)	(18,910)	(23,412)	(35,718)	(43,883)
Profit Before Tax (FRS 3)		(14,327)	(17,962)	(47,484)	(27,476)	(47,783)
Tax		(98)	(2)	0	0	0
Profit After Tax (norm)		(21,692)	(18,721)	(23,229)	(35,679)	(43,783)
Profit After Tax (FRS 3)		(14,425)	(17,964)	(47,484)	(27,476)	(47,783)
Average Number of Shares Outstanding (m)		17.9	23.0	32.9	50.5	51.0
EPS - normalised (c)		(120.9)	(81.5)	(70.6)	(70.6)	(85.8)
EPS - normalised fully diluted (c)		(120.9)	(55.1)	(48.8)	(62.4)	(75.9)
EPS - (IFRS) (c)		(80.4)	(78.2)	(144.4)	(54.4)	(93.6)
Dividend per share (c)		0.0	0.0	0.0	0.0	0.0
Gross Margin (%)		100.0	100.0	N/A	N/A	N/A
EBITDA Margin (%)		N/A	N/A	N/A	N/A	N/A
Operating Margin (before GW and except) (%)		N/A	N/A	N/A	N/A	N/A
<b>BALANCE SHEET</b>						
Fixed Assets		573	539	476	339	212
Intangible Assets		184	184	184	184	184
Tangible Assets		266	253	175	38	(89)
Investments		123	102	117	117	117
Current Assets		37,282	39,666	41,024	86,527	42,771
Stocks		0	0	0	0	0
Debtors		176	110	117	31	31
Cash		36,047	38,344	38,568	84,296	40,540
Other		1,059	1,212	2,338	2,200	2,200
Current Liabilities		(13,600)	(10,066)	(30,839)	(16,797)	(16,797)
Creditors		(6,861)	(6,094)	(6,656)	(7,318)	(7,318)
Deferred revenue		(6,739)	(3,972)	(24,182)	(9,479)	(9,479)
Short term borrowings		0	0	0	0	0
Long Term Liabilities		0	0	0	0	0
Long term borrowings		0	0	0	0	0
Other long term liabilities		0	0	0	0	0
Net Assets		24,255	30,139	10,662	70,068	26,186
<b>CASH FLOW</b>						
Operating Cash Flow		(16,671)	(19,045)	(22,704)	(35,384)	(43,963)
Net Interest		0	0	138	300	200
Tax		0	0	0	0	0
Capex		(53)	(135)	0	7	7
Acquisitions/disposals		6,938	0	0	0	0
Financing		18,940	21,477	24,095	80,805	0
Dividends		0	0	0	0	0
Other		0	0	0	0	0
Net Cash Flow		9,154	2,297	1,528	45,728	(43,756)
Opening net debt/(cash)		(26,892)	(36,047)	(38,344)	(38,568)	(84,296)
HP finance leases initiated		0	0	0	0	0
Other		1	0	(1,304)	0	0
Closing net debt/(cash)		(36,047)	(38,344)	(38,568)	(84,296)	(40,541)

Source: Company accounts, Edison Investment Research

Edison, the investment intelligence firm, is the future of investor interaction with corporates. Our team of over 100 analysts and investment professionals work with leading companies, fund managers and investment banks worldwide to support their capital markets activity. We provide services to more than 400 retained corporate and investor clients from our offices in London, New York, Frankfurt, Sydney and Wellington. Edison is authorised and regulated by the Financial Conduct Authority ([www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584](http://www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584)). Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only. Edison Investment Research Inc (Edison US) is the US subsidiary of Edison and is regulated by the Securities and Exchange Commission. Edison Investment Research Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison and is not regulated by the Australian Securities and Investment Commission. Edison Germany is a branch entity of Edison Investment Research Limited [4794244]. [www.edisongroup.com](http://www.edisongroup.com)

#### DISCLAIMER

Copyright 2014 Edison Investment Research Limited. All rights reserved. This report has been commissioned by CytRx and prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The securities described in the Investment Research may not be eligible for sale in all jurisdictions or to certain categories of investors. This research is issued in Australia by Edison Aus and any access to it, is intended only for "wholesale clients" within the meaning of the Australian Corporations Act. The Investment Research is distributed in the United States by Edison US to major US institutional investors only. Edison US is registered as an investment adviser with the Securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. As such, Edison does not offer or provide personalised advice. We publish information about companies in which we believe our readers may be interested and this information reflects our sincere opinions. The information that we provide or that is derived from our website is not intended to be, and should not be construed in any manner whatsoever as, personalised advice. Also, our website and the information provided by us should not be construed by any subscriber or prospective subscriber as Edison's solicitation to effect, or attempt to effect, any transaction in a security. The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. This document is provided for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research. Edison has a restrictive policy relating to personal dealing. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report. Edison or its affiliates may perform services or solicit business from any of the companies mentioned in this report. The value of securities mentioned in this report can fall as well as rise and are subject to large and sudden swings. In addition it may be difficult or not possible to buy, sell or obtain accurate information about the value of securities mentioned in this report. Past performance is not necessarily a guide to future performance. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a "personalised service" and, to the extent that it contains any financial advice, is intended only as a "class service" provided by Edison within the meaning of the FAA (ie without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision. To the maximum extent permitted by law, Edison, its affiliates and contractors, and their respective directors, officers and employees will not be liable for any loss or damage arising as a result of reliance being placed on any of the information contained in this report and do not guarantee the returns on investments in the products discussed in this publication. FTSE International Limited ("FTSE") © FTSE 2014. "FTSE®" is a trade mark of the London Stock Exchange Group companies and is used by FTSE International Limited under license. All rights in the FTSE indices and/or FTSE ratings vest in FTSE and/or its licensors. Neither FTSE nor its licensors accept any liability for any errors or omissions in the FTSE indices and/or FTSE ratings or underlying data. No further distribution of FTSE Data is permitted without FTSE's express written consent.